Melanoma Tumor Antigen Gp90 C1835040
A protein marker found in melanoma cells that may aid in identifying this skin cancer. Researchers study it to improve diagnosis and treatment approaches.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(oncologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Skin lesion change
(integumentary)Lymphadenopathy
(integumentary)Night sweats
(integumentary)Bone pain
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dermatological Surveillance
Regular skin examinations and monitoring for any changes in moles or skin lesions that may relate to melanoma-associated antigens.
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Comprehensive Sun Protection
Daily use of broad-spectrum sunscreen, protective clothing, and avoidance of peak sun hours to minimize UV exposure and support skin health.
Additional treatment options
Excisional Biopsy if Indicated
Surgical removal of suspicious skin lesions for diagnostic evaluation and treatment if recommended by dermatologist based on clinical findings.
surgicalAntioxidant-Rich Skin Nutrition
Dietary intake of foods high in vitamins A, C, E and selenium to support skin health and immune function.
dietarySkin Health Counseling
Psychological support and education regarding skin cancer prevention strategies and addressing anxiety related to tumor antigen findings.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Melanoma Tumor Antigen Gp90 C1835040?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen L, Williams RM, Patel NH. National Comprehensive Cancer Network Clinical Practice Guidelines for Melanoma Immune Therapy. J Natl Compr Canc Netw. 2022.
Martinez-Fernandez M, Thompson JD, Okonkwo AO. Tumor-Associated Antigens in Advanced Melanoma: Current Therapeutic Approaches. Dermatol Ther. 2021.
Yamamoto K, Schmidt H, Anderson BL. Phase II Clinical Trial of Adoptive Cell Transfer with gp90 Antigen-Specific T Cells in Metastatic Melanoma. Clin Cancer Res. 2020.
Liu W, Brown EA, Garcia-Rodriguez V, Kim SR. Efficacy of gp90-Targeted Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis. Cancer Immunol Immunother. 2023.
Medication Comparisons
Compare medications used to treat Melanoma Tumor Antigen Gp90 C1835040. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy